替雷利珠单抗治疗复发或难治性经典型霍奇金淋巴瘤的2期单臂多中心研究结果
中位随访9.8个月后,独立评审委员会评估的客观缓解率为87.1%,完全缓解率为62.9%,估计9个月无进展生存率为74.5%。治疗总体耐受良好,最常见≥3级不良事件为上呼吸道感染和肺炎。
要点
- 替雷利珠单抗在R/R cHL中客观缓解率87.1%,完全缓解率62.9%
- 估计9个月无进展生存率为74.5%
- 最常见≥3级不良事件为上呼吸道感染和肺炎
核心结论
- 替雷利珠单抗治疗复发/难治性经典型霍奇金淋巴瘤总体耐受良好,客观缓解率和完全缓解率高,可能转化为更持久的缓解。
研究设计与样本
- 主要终点为独立评审委员会按Lugano 2014分类评估的客观缓解率。
主要发现
- 中位随访9.8个月后,61例(87.1%)患者达到客观缓解,44例(62.9%)达到完全缓解。
- 估计9个月无进展生存率为74.5%。
- 最常见≥3级不良事件为上呼吸道感染和肺炎。
- 输液相关反应发生于27例(38.6%)患者,27例(38.6%)发生免疫相关不良事件,最常见为甲状腺功能障碍。
临床怎么用
- 对于自体干细胞移植后失败或不适合移植的复发/难治性经典型霍奇金淋巴瘤患者,替雷利珠单抗可提供高缓解率的治疗选择。
- 治疗期间需关注上呼吸道感染、肺炎、输液相关反应及免疫相关不良事件(如甲状腺功能障碍)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prognosis is poor for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after failure of or who are ineligible for autologous stem cell transplant. We evaluated the efficacy and safety of tislelizumab, an investigational anti-PD-1 monoclonal antibody, in phase 2, single-arm study in Chinese patients with R/R cHL. The primary endpoint was overall response rate as assessed by an independent review committee, according to the Lugano 2014 Classification. Seventy patients were enrolled in the study and received at least one dose of tislelizumab. After median follow-up of 9.8 months, 61 (87.1%) patients achieved an objective response, with 44 (62.9%) achieving a complete response (CR). The estimated 9-month progression-free survival rate was 74.5%. Most common grade ≥3 adverse events (AEs) were upper respiratory tract infection and pneumonitis. Infusion-related reactions occurred in 27 (38.6%) patients, and 27 patients (38.6%) experienced an immune-related AE, the most common of which was thyroid dysfunction. Eleven (15.7%) patients experienced at least one treatment-emergent AE leading to dose interruption or delay. No deaths occurred due to AEs. Treatment of patients with R/R cHL with tislelizumab was generally well tolerated and resulted in high overall response and CR rates, potentially translating into more durable responses for these patients.
引用
- Song Y, Gao Q, Zhang H, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2019. PMID: 31520078. doi:10.1038/s41375-019-0545-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。